Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.5%

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) rose 4.5% on Thursday . The stock traded as high as $35.32 and last traded at $35.28. Approximately 318,646 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 742,994 shares. The stock had previously closed at $33.76.

Analyst Upgrades and Downgrades

KYMR has been the subject of several research analyst reports. JPMorgan Chase & Co. increased their price objective on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Truist Financial upped their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Wolfe Research started coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Bank of America cut Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $45.00 to $30.00 in a research note on Wednesday, January 3rd. Finally, Piper Sandler upped their price target on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $39.89.

Kymera Therapeutics Price Performance

The company has a 50-day simple moving average of $39.20 and a 200-day simple moving average of $27.68.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.19. The company had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. Kymera Therapeutics’s revenue was up 197.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.60) earnings per share. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -3.13 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the sale, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bruce Booth sold 71,764 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the sale, the director now owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 3,934 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now directly owns 142,351 shares in the company, valued at approximately $5,958,812.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 484,051 shares of company stock valued at $19,924,711. Insiders own 16.67% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 5.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company’s stock valued at $135,848,000 after acquiring an additional 278,287 shares during the last quarter. BVF Inc. IL boosted its stake in Kymera Therapeutics by 8.9% in the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company’s stock worth $131,419,000 after buying an additional 422,797 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock worth $101,778,000 after buying an additional 72,351 shares during the last quarter. State Street Corp boosted its stake in Kymera Therapeutics by 67.8% in the 2nd quarter. State Street Corp now owns 3,514,438 shares of the company’s stock worth $69,199,000 after buying an additional 1,419,877 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Kymera Therapeutics by 0.6% in the 1st quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after buying an additional 21,544 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.